Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
IGF-1 LR3 vs. Tirzepatide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both are included in the Relay research library, but their current records answer substantially different questions.
⇄ Different
Biggest Difference
IGF-1 LR3 is distinguished by a modified IGF-1 analogue engineered for low binding-protein affinity. Its direct evidence is laboratory and animal—not the approved human record for native recombinant IGF-1; Tirzepatide is distinguished by dual agonist at GIP and GLP-1 receptors, with approved U.S. products and a much larger completed evidence base.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
IGF-1 LR3 is distinguished in the current record by a modified IGF-1 analogue engineered for low binding-protein affinity. Its direct evidence is laboratory and animal—not the approved human record for native recombinant IGF-1. Tirzepatide is distinguished by dual agonist at GIP and GLP-1 receptors, with approved U.S. products and a much larger completed evidence base. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceTirzepatide
IGF-1 LR3: Preclinical evidence. Tirzepatide: Mature human evidence.
Regulatory historyTirzepatide
IGF-1 LR3: Not FDA approved — preclinical evidence only. Tirzepatide: FDA approved for defined indications.
Mechanistic breadthIGF-1 LR3
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
IGF-1 LR3
- Muscle-protein preservation — animal evidence
- Whole-body and organ growth — inconsistent animal evidence
- Glucose lowering — animal risk signal
- Cancer-cell proliferation — laboratory evidence
Tirzepatide
- Obesity
- Type 2 diabetes
- Cardiometabolic outcomes
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
IGF-1 LR3Not FDA approved
Not FDA approved. A peer-reviewed anti-doping paper states that LR3 and related analogues were never approved for human use and are prohibited in sport.
TirzepatideFDA-labeled indications
FDA approved as Mounjaro for type 2 diabetes and Zepbound for defined adult weight-management and OSA indications.
Evidence depthEvidence, not a winner
IGF-1 LR3Preclinical only
Multiple animal, laboratory, and analytical studies; no direct human efficacy, safety, pharmacokinetic, or dose-finding study located.
TirzepatideMature Phase 3
Multiple large Phase 3 trials, active-comparator studies, 176-week follow-up, a 13,299-participant cardiovascular outcomes trial, and newer 2026 maintenance data.
Weight outcomesEvidence, not a winner
IGF-1 LR3No human evidence
No controlled human weight-loss or body-composition evidence. Animal growth effects were inconsistent and sometimes negative.
TirzepatidePeer-reviewed Phase 3
SURMOUNT-1 peer-reviewed trial: mean change −15.0%, −19.5%, and −20.9% across studied doses versus −3.1% placebo at 72 weeks.
Type 2 diabetesEvidence, not a winner
IGF-1 LR3Animal glucose-risk signal
No human diabetes-treatment evidence. Animal studies show stronger and more prolonged glucose lowering than native IGF-I—a risk signal, not a validated therapy.
TirzepatideApproved + Phase 3
Extensive SURPASS program and FDA approval. SURPASS-2 directly compared tirzepatide with semaglutide 1 mg in type 2 diabetes.
Obstructive sleep apnoeaEvidence, not a winner
IGF-1 LR3No human evidence
No controlled human obstructive-sleep-apnoea evidence was located.
TirzepatideApproved + Phase 3
Two peer-reviewed Phase 3 trials support the FDA-approved Zepbound indication for moderate-to-severe OSA in adults with obesity.
Cardiovascular outcomesEvidence, not a winner
IGF-1 LR3No human outcome evidence
No human cardiovascular-outcome evidence was located. General IGF pathway biology cannot substitute for LR3 outcome trials.
TirzepatideCVOT + HFpEF trial
SURPASS-CVOT found tirzepatide noninferior—but not superior—to dulaglutide for major cardiovascular events. In SUMMIT, a separate placebo-controlled HFpEF-and-obesity population had fewer composite cardiovascular-death or worsening-heart-failure events; that finding is population-specific.
Administration and handlingEvidence, not a winner
IGF-1 LR3No validated human protocol
Published LR3 protocols are animal or laboratory exposures. No evidence-based human route, dose, cycle, reconstitution, or monitoring standard was identified.
TirzepatideOfficial FDA label
FDA labels provide product-specific once-weekly subcutaneous dosing and handling. Approved presentations are solutions; no reconstitution is required.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Human pharmacokinetics, glucose risk, long-term proliferative and organ effects, feedback suppression, and real-world product identity.
- Long-term individual durability and rare events, plus evidence for uses outside studied and approved populations.
Community Intelligence
Emerging patterns, clearly separated from evidence
IGF-1 LR3
No community experiences yetBe the first account holder to contribute.
Tirzepatide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.